Toggle navigation
Home
Search
Services
Blog
Contact
About
Preclinical Efficacy and Intermediate Endpoint Assays
Search grants from
Share this grant:
:
:
Abstract
Funding
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Engineered Cardiac Tissue with Biomimetic Architecture and Vasculature
Highly multiplexed and mutation-sensitive quantitative PCR for cancer diagnostics
Does psychological wellness predict treatment response?
Pediatric Epilepsy Surgery Research Program
Partnership for Excellence in Biomedical Science
Recently added grants:
SARM1 functional polymorphisms and their contribution to ALS risk
Cortical circuit mechanisms of visual shape processing
Optical control of endogenous G protein Coupled Receptor and G Protein Signaling.
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer
Characterization of biased airway smooth muscle TAS2R agonists for treating asthma
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN43309-8-0-1
Application #
7587179
Study Section
Project Start
2004-05-15
Project End
2009-05-14
Budget Start
Budget End
Support Year
Fiscal Year
2007
Total Cost
Indirect Cost
Related projects
NIH 2008
N01 CA
Preclinical Efficacy and Intermediate Endpoint Assays
/ Fox Chase Cancer Center
$2,364,525
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Biomarker Assays
Clapper, Margie /
$1,632,611
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Endpoint Assays
/
Comments
Be the first to comment on this grant